CD36 Knockout THP-1 Cell Line

Description

CD36 Knockout THP-1 Cell Line is engineered from the human monocytic THP-1 cell line using CRISPR/Cas9 technology to disrupt the Cluster of Differentiation 36 (CD36) gene, a key scavenger receptor involved in fatty acid uptake, phagocytosis, and inflammatory responses. As suspension cells with round morphology, these knockout THP-1 cells exhibit impaired lipid metabolism and modified immune functions, making them particularly valuable for research on atherosclerosis, metabolic disorders, and infectious diseases. The cell line maintains stable growth at low passage numbers (<P20), with knockout efficiency verified through PCR, Sanger sequencing, or Western blot analysis. All cells undergo stringent quality control and are confirmed free of contamination from HIV-1, HBV, HCV, Syphilis, mycoplasma, fungi, yeast, and bacteria.